Pricing

Kura Oncology Inc (KURA)

followers ·
Sector: HEALTH CARE
Industry: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS
CEO: Troy E. Wilson
Employees: 130
Web site: kuraoncology.com
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA, 92130
(858) 500-8800
    Formally known as:
  • KURA ONCOLOGY INC COM
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Kura Oncology, Inc. develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction. tipifarnib, an orally bioavailable inhibitor of farnesyl transferase, is in Phase II clinical trials for the. treatment of solid tumors and hematologic indications.
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available